CD274 and non-small cell lung carcinoma: Most recently, in 2016, the FDA approved the VENTANA PD-L1 (SP142) assay as a companion diagnostic for selecting patients with NSCLC and bladder cancer for treatment with Atezolizumab (TECENTRIQ) [6].